Glucose Metabolism Disorders and Metabolic Syndrome Before and After Primary Hip and Knee Replacement

Hyperglycemia in Joint Replacement Recipients: Glucose Metabolism Disorders and Metabolic Syndrome in Osteoarthritis Patients Before and After Primary Hip and Knee Replacement

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01743313

Acronym

HyTe-2

Enrollment

155

Registered

2012-12-06

Start date

2012-04-30

Completion date

2017-06-30

Last updated

2023-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Replacement, Hypercholesterolemia, Hyperglycemia, Knee Replacement, Persistent Postoperative Pain

Keywords

glucose metabolism disorders, metabolic syndrome, joint replacement, osteoarthritis

Brief summary

Osteoarthritis patients undergoing primary hip and knee replacement are followed-up and changes in their glucose metabolism and other metabolic parameters (obesity, cholesterol levels) are examined. Persistent postoperative pain is examined as secondary outcome.

Detailed description

Glucose metabolism disorders (diabetes and pre-diabetes) and metabolic syndrome are common in joint replacement recipients. Improved physical activity following joint replacement could lead to better glucose control in diabetes and ameliorate impaired glucose and cholesterol levels. In this study patients previously recruited to Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study are being followed-up for one year in order to analyze if joint replacements have an effect on these metabolic abnormalities. In addition, the effect of glucose metabolism disorders on occurrence of persistent pain after surgery is analyzed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

* Primary hip and knee replacement for osteoarthritis * Enrolled previously into study NCT01021826

Exclusion criteria

* Arthritis other than osteoarthritis (based on study NCT01021826) * Medication affecting glucose metabolism (excl. antidiabetic agents) (based on study NTC01021826) * Died before follow-up phase * Did not undergo the planned hip or knee replacement

Design outcomes

Primary

Measure	Time frame	Description
Change in glucose tolerance, measured using oral glucose tolerance test	Baseline and 12-24 months after surgery	The patients are grouped into three groups that are evaluated 12, 18 and ca. 24 months after surgery.

Secondary

Measure	Time frame	Description
Change in cholesterol levels (HDL, LDL, triglycerides)	Baseline and 12-24 months after surgery	—
Prolonged postoperative pain	12-24 months after surgery	Assessed using visual analog scale. Patients are divided in three groups that are evaluated 12, 18 and 24 months after surgery.

Other

Measure	Time frame
Change in plasma adipokine and cytokine concentrations	Baseline and 12-24 months after surgery.

Countries

Finland

Outcome results